Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
15 studies found for:    CSF1R
Show Display Options
Rank Status Study
1 Recruiting Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers
Conditions: Colorectal Cancer;   Pancreatic Cancer;   Metastatic Cancer;   Advanced Cancer
Interventions: Drug: Pexidartinib;   Drug: Durvalumab
2 Recruiting A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Conditions: Melanoma;   Non-small Cell Lung Cancer;   Ovarian Cancer;   Triple-negative Breast Cancer;   Squamous Cell Carcinoma of the Head and Neck;   Bladder Cancer;   Pancreatic Ductal Adenocarcinoma;   Gastric Cancer
Interventions: Drug: PLX3397;   Biological: Pembrolizumab
3 Recruiting A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
Condition: Solid Tumor
Interventions: Drug: LY3022855;   Drug: Durvalumab;   Drug: Tremelimumab
4 Recruiting A Study of IMC-CS4 in Subjects With Advanced Solid Tumors
Condition: Neoplasms
Intervention: Biological: IMC-CS4
5 Recruiting Study of FPA008 in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor
Conditions: Pigmented Villonodular Synovitis;   Tenosynovial Giant Cell Tumor
Intervention: Drug: FPA008
6 Recruiting Study of FPA008 in Combination With Nivolumab in Patients With Selected Advanced Cancers
Conditions: Advanced Solid Tumors, Including But Not Limited to Lung Cancer;   Head and Neck Cancer;   Pancreatic Cancer;   Ovarian Cancer;   Renal Cell Carcinoma;   Malignant Glioma
Interventions: Biological: FPA008;   Biological: BMS-936558
7 Recruiting Colony-Stimulating Factor-1 (CSF-1) and Other Cytokines in Human Endometrial Carcinogenesis
Conditions: Uterine Neoplasms;   Endometrial Neoplasms
Intervention:
8 Completed
Has Results
Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST)
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: dovitinib
9 Completed To Assess the Interaction Between Sunitinib and Ketoconazole to Reduce the Dose and Cost of Sunitinib
Condition: Cancer
Interventions: Drug: Sunitinib;   Drug: Sunitinib and Ketoconazol;   Drug: Sunitiinb and Ketoconazol
10 Active, not recruiting PLX3397 Phase 3 Study for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)
Conditions: Pigmented Villonodular Synovitis;   Giant Cell Tumors of the Tendon Sheath;   Tenosynovial Giant Cell Tumour
Interventions: Drug: PLX3397 capsule;   Drug: Placebo capsule matching PLX3397 capsule
11 Recruiting Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors
Condition: Advanced Solid Tumors
Interventions: Drug: BLZ945;   Drug: PDR001
12 Recruiting TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Conditions: Lymphoma, Non-Hodgkin;   Multiple Myeloma;   Advanced Solid Tumors
Interventions: Drug: Erlotinib;   Drug: Axitinib;   Drug: Bosutinib;   Drug: Crizotinib;   Drug: Palbociclib;   Drug: Sunitinib;   Drug: Temsirolimus;   Drug: Trastuzumab and Pertuzumab;   Drug: Vemurafenib and Cobimetinib;   Drug: Vismodegib;   Drug: Cetuximab;   Drug: Dasatinib;   Drug: Regorafenib;   Drug: Olaparib;   Drug: Pembrolizumab
13 Completed A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers
Condition: Metastatic Cancer
Intervention: Drug: ARRY-382, cFMS inhibitor; oral
14 Recruiting Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: My Own Specific Treatment
Condition: Malignant Solid Neoplasms
Interventions: Drug: Nilotinib (400 mg BID);   Drug: Everolimus (10 mg QD);   Drug: Sorafenib (400 mg BID);   Drug: Lapatinib (1500 mg QD);   Drug: Pazopanib (800 mg QD)
15 Active, not recruiting A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors
Condition: Advanced Solid Tumors
Interventions: Drug: Paclitaxel;   Drug: RO5509554

Study has passed its completion date and status has not been verified in more than two years.